Compare BRC & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRC | PBLS |
|---|---|---|
| Founded | 1914 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.4B |
| IPO Year | 2005 | 2026 |
| Metric | BRC | PBLS |
|---|---|---|
| Price | $93.17 | $28.81 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.20 | N/A |
| AVG Volume (30 Days) | 232.3K | ★ 545.1K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,144,698,000.00 | N/A |
| Revenue This Year | $7.36 | N/A |
| Revenue Next Year | $3.57 | N/A |
| P/E Ratio | $23.35 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $68.11 | $25.56 |
| 52 Week High | $99.29 | $33.65 |
| Indicator | BRC | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 52.17 |
| Support Level | $88.79 | $26.96 |
| Resistance Level | $95.87 | $30.90 |
| Average True Range (ATR) | 2.30 | 2.39 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 63.71 | 30.56 |
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.